Opus_RGB.jpg
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
November 11, 2021 10:36 ET | Opus Genetics
RALEIGH, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced an agreement to...
Opus_RGB.jpg
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
November 08, 2021 08:30 ET | Opus Genetics
RALEIGH, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced that Ben Yerxa,...
Opus_RGB.jpg
Opus Genetics Announces Two Key Leadership Appointments
October 20, 2021 07:30 ET | Opus Genetics
Dr. Ash Jayagopal named Chief Scientific OfficerMr. Joe Schachle appointed Chief Operating Officer RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy...
Opus_RGB.jpg
RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
September 22, 2021 07:30 ET | Opus Genetics
Initial programs will focus on treatments for rare pediatric blinding conditions Company formed to advance the work of scientific cofounders Dr. Jean Bennett, Junwei Sun and Dr. Eric Pierce ...